Story
Saw Palmetto · Serenoa repens
Last updated
In one pass Saw palmetto is the most common herbal supplement sold for an enlarged prostate.
Educational content, not medical advice — consult a clinician.
Story path
Chapter 1
Enlarged prostate and saw palmetto
Saw palmetto is the most common herbal supplement sold for an enlarged prostate. Its selling point sounds plausible as a mechanism, yet in large, rigorously designed trials it did no better than placebo.
Start with the problem it is sold to fix. The prostate does not sit beside the urethra; it wraps all the way around it, like a doughnut slipped over a hose, so when it thickens, the hose is what gets squeezed. With age, testosterone inside prostate cells is rewritten by 5α-reductase into DHT (dihydrotestosterone), which binds its receptor far more strongly, and DHT drives the gland and the surrounding stroma (which holds a lot of smooth muscle) to grow. With the urethra cinched, the stream is slow to start, runs thin, and never feels finished; the bladder, pushing against that narrow outlet every day, turns sensitive itself and wants to go when only a little has collected. That is benign prostatic hyperplasia (BPH).
Saw palmetto's pitch lands at the very top of this chain: in a test tube, it can block the enzyme that rewrites testosterone.
If one day you cannot pass urine at all and your lower belly is swollen and painful, that is acute urinary retention: go to the emergency department now, and do not wait for any supplement to work.
Start with the problem it is sold to fix. The prostate does not sit beside the urethra; it wraps all the way around it, like a doughnut slipped over a hose, so when it thickens, the hose is what gets squeezed. With age, testosterone inside prostate cells is rewritten by 5α-reductase into DHT (dihydrotestosterone), which binds its receptor far more strongly, and DHT drives the gland and the surrounding stroma (which holds a lot of smooth muscle) to grow. With the urethra cinched, the stream is slow to start, runs thin, and never feels finished; the bladder, pushing against that narrow outlet every day, turns sensitive itself and wants to go when only a little has collected. That is benign prostatic hyperplasia (BPH).
Saw palmetto's pitch lands at the very top of this chain: in a test tube, it can block the enzyme that rewrites testosterone.
If one day you cannot pass urine at all and your lower belly is swollen and painful, that is acute urinary retention: go to the emergency department now, and do not wait for any supplement to work.
Mechanism · Why a thicker gland blocks the flow
The prostate presses on the urethra through two forces working together: one static, one dynamic.The static force is volume. Gland cells and the stromal cells between them keep multiplying until they fill the capsule wrapped around the outside. The capsule will not give, so the new tissue can only push inward, and the urethra is flattened. The only way to take this force off is for the gland to actually shrink back — which is why the prescription drugs that block the converting enzyme take months to work: tissue remodeling is slow by nature.
The dynamic force is tone. The prostate and the bladder neck are packed with smooth muscle, densely covered in a receptor that picks up sympathetic nerve signals (the α₁ receptor); when the sympathetic system fires, that muscle tightens. This force can let go without any change in volume — which is why the drugs that relax smooth muscle can thicken the stream within weeks.
Separating the two forces explains something that often puzzles people: two prostates of the same size, and one man gets up three times a night while the other barely notices. What the doctor measures is volume; what you feel is volume plus tone.
The bladder is the second victim. Once the outlet is cinched, the bladder has to push at higher pressure to move urine. The muscle of the bladder wall (the detrusor) thickens the way a muscle does under daily strength training, and thicker muscle is more likely to fire on its own, so the storage phase starts to hurt: urgency before much is in, more and more trips to the toilet, waking at night. That half of the symptoms is not the prostate acting directly; it is the bladder being forced into it. That is why some men, once the obstruction is relieved, get a free stream on the spot while the urgency takes a while longer to fade.
With this chain in hand, you can work a lot out for yourself. Anything that tightens that ring of smooth muscle, or fills the bladder faster, makes the same prostate behave worse: the decongestant in a cold remedy (its whole job is to tighten smooth muscle), cold weather, holding it in, a large drink of alcohol before bed. Turn it around and the lifestyle advice in Other treatments and side effects stops being consolation: it moves exactly these two variables.
Background · What the berry actually is
Saw palmetto is the berry of a plant called Serenoa repens. It belongs to the palm family (Arecaceae) and is native to the southeastern United States — the swamps and sandy ground of Florida, South Carolina and Georgia. The plant is a short, shrub-like palm whose leaves have saw-toothed edges, hence the name.The part used is the ripe berry: deep purple-black, oily, and rich in fatty acids and plant sterols. Native Americans (the Seminole, the Creek and others) traditionally used it for male reproductive health, to increase urine flow and for vigor; in the late 19th century it reached Europe, where it was used for prostate and bladder symptoms.
The oily part will matter later. The components thought to be active sit in the fat-soluble fraction, so almost every product on the market is an oil extract rather than a dry powder. The oil extract came with an unexpected by-product: an odor that is hard to hide. The whole evidence story eventually snags on that odor — it probably made it hard for the early trials to be truly double-blind.
Clinical · How common BPH is, and how it feels
The problem it is sold to solve is benign prostatic hyperplasia (BPH), and it is very common. Pooled autopsy studies (Berry 1984) found hyperplasia under the microscope in about 50% of men in their fifties, and the share keeps rising with age. About half of those men develop lower urinary tract symptoms (LUTS): going often, getting up at night, trouble starting, a weak stream, a sense of not having emptied, urgency.Watch the gap between those two numbers. Far more men have hyperplastic nodules a pathologist can see than men who get up at night because of them. Two gates sit in between: where the growth sits (a little growth hugging the urethra already blocks the way; growth in the outer, peripheral zone can be large and bother no one), and how well your bladder can cope.
So "men my age all have prostate problems" is a sentence with no information in it. Having it on a microscope slide and being affected in daily life are two different things. What decides whether you suffer is not whether you have it, but where it cinches, how tight, and how much reserve your bladder has left.
That is also why doctors care more about symptom scores and flow rate than about a single volume number.
Background · Why it sounds right, and why it sells
There are four mechanism hypotheses for saw palmetto:It inhibits the enzyme that rewrites testosterone into DHT: this works in vitro; whether the dose that reaches the body is enough is doubtfulIt is anti-inflammatory and reduces swelling: attributed to its fatty acids and sterolsIt modulates α-receptors: speculative, weak evidenceIt binds the androgen receptor: with low affinity, and the data come from animals
The first looks most persuasive, because it sits at the very top of the chain. But the words works in vitro hide a long distance. In a dish, the concentration is whatever the experimenter dials in; if they want the enzyme to stop, they turn the concentration up until it does. A capsule first has to be absorbed through the gut, then metabolized by the liver, then spread through the whole body by the blood, and the amount that finally bathes prostate tissue can be orders of magnitude below the dish concentration. Works in vitro is therefore only a ticket in, not a conclusion.
A mechanism that sounds reasonable is not the same as clinically effective. That mismatch is one of the most common in nutritional medicine, and saw palmetto is the textbook counterexample.
Why it has kept selling for so long has several layers. In Europe, Germany and France once used standardized saw palmetto extracts (Permixon®, SabalSelect® and others) as a common treatment for BPH. In the United States, after the 1994 DSHEA law, it became one of the best-selling men's supplements. Natural, no doctor visit, no side effects is a strong pull for middle-aged men. Before 2000, small randomized trials were mostly positive, and that became the marketing foundation; after 2006, large trials came back negative one after another, but market inertia and marketing carried on.
Chapter 2
Why early trials looked positive
BPH symptom scores are reported by you — how many times you got up last night, how thin the stream felt, whether you emptied — all recalled and then scored. Scores like that tend to improve on their own: symptoms already change from week to week, and anyone who feels they are being treated tends to score themselves kinder.
So these trials rise or fall on one thing: whether participants can tell the real capsule from the dummy. Saw palmetto happens to be an oil capsule with a very particular smell (like tomato mixed with spoiled berries). The placebos in the early trials probably could not copy it, and some participants may well have guessed their group the moment they opened the bottle.
That produced the decade or so when it looked effective: small samples, short follow-up, many trials paid for by manufacturers, negative results less likely to be published, plus a mechanism that sounded entirely reasonable. The 2002 Cochrane systematic review pooled those trials and concluded that it gave a mild to moderate improvement in urinary symptoms and flow, similar to the prescription drug finasteride, with fewer side effects.
So these trials rise or fall on one thing: whether participants can tell the real capsule from the dummy. Saw palmetto happens to be an oil capsule with a very particular smell (like tomato mixed with spoiled berries). The placebos in the early trials probably could not copy it, and some participants may well have guessed their group the moment they opened the bottle.
That produced the decade or so when it looked effective: small samples, short follow-up, many trials paid for by manufacturers, negative results less likely to be published, plus a mechanism that sounded entirely reasonable. The 2002 Cochrane systematic review pooled those trials and concluded that it gave a mild to moderate improvement in urinary symptoms and flow, similar to the prescription drug finasteride, with fewer side effects.
Evidence · What the 2002 Cochrane review said
From the 1990s to around 2005, saw palmetto spent about 10 years looking effective. The landmark of that period is the 2002 Cochrane systematic review (Wilt and colleagues):It included 21 randomized trials with 3,139 men in totalAgainst placebo: less nocturia and a higher maximum urinary flow rateAgainst finasteride: similar improvement in symptom scores, with fewer side effectsThe authors' conclusion: a mild to moderate improvement in urinary symptoms and flow; long-term effectiveness, safety, and whether it could prevent BPH complications were not yet known
Where that pooled result went wrong. It added up a pile of individually small trials and got a total sample size that looks impressive. Sample size can crush random noise — this man gets up one extra time today, that man one fewer time tomorrow; with enough people, the jitter cancels out. It cannot crush systematic bias: if in every trial the participants could smell whether they had the real thing, stacking those trials only makes the same bias look more significant, not closer to the truth.
That is almost the whole reason the two Cochrane editions came out opposite. Later researchers were not smarter. Later trials finally plugged the odor hole, and they were bigger and longer.
Evidence · Why early trials came out positive
The mostly positive early randomized trials can be taken apart into five causes:1. Small and short. Most trials had fewer than 100 people and ran 8-12 weeks. In a condition scored by how people feel, like BPH, the placebo effect is very strong (symptoms fluctuate by themselves, and expectation adds to it), and a small sample cannot separate a true effect from placebo noise.
2. Poor blinding. Saw palmetto oil capsules have a characteristic smell (like tomato mixed with rotting berries); a placebo that smells the same is hard to make, so the double-blind may break.
3. High heterogeneity. The trials used different extracts, doses and patients of different severity; positive results often came from men with mild symptoms on small doses, who were likely to improve on their own anyway.
4. Publication bias. Negative trials were less likely to be published, and many early positive trials were funded by manufacturers.
5. The halo of a plausible mechanism. 5α-reductase inhibition works in vitro, which makes a positive result sound right, and reviewers and readers alike prefer a story that makes sense.
The five are not side by side; they amplify each other. Once blinding breaks, the placebo effect is counted straight into the drug effect; once the sample is small, that extra drug effect looks large enough; and a mechanism that sounds right made everyone along the chain — the people running the trial, the people reviewing it, the people reading it — ask one question fewer. No one of them alone is enough to manufacture a false conclusion. All five together are.
Background · Early positives, overturned by big trials
Saw palmetto followed a road that is common in nutrition: a positive early signal, then large trials that do not bear it out. A few other examples:β-carotene: early observational studies looked favorable; in two randomized trials, ATBC and CARET, smokers who took it had more lung cancer, not less.Vitamin E: early observational studies looked favorable; in the SELECT randomized trial, prostate cancer went up, not down.Multivitamins: early observational studies showed a signal; in the PHS-II randomized trial, there was no overall protection against atherosclerotic cardiovascular disease ().
What they share: a mechanism that sounds right, a positive early signal, and large randomized trials that came back negative or pointed the other way. Saw palmetto's early evidence came from small randomized trials rather than observational studies, but the road was the same. The lesson: until a large, independent randomized trial is in, it works is an unfinished draft, not a conclusion.
For saw palmetto, three pieces of evidence came back negative: the STEP trial published in 2006 (funded by the US National Institutes of Health, NIH, with no manufacturer involved), the 2011 CAMUS dose-escalation trial, and the Cochrane systematic review updated in 2012.
Chapter 3
Large trials found no effect
To stop participants telling real from fake, the smell had to be dealt with first. The STEP trial did it simply: the placebo was given a melted-cheese flavor, so it smelled just as odd. This time, the people taking capsules could hardly guess which group they were in.
A year later, the two groups' symptom scores almost overlapped, flow rates were the same, and prostate volume had crept up a little in both groups, again with no difference. The gap was so small that if you drew the two curves together you would think you had drawn one twice.
Then came the objection: maybe the dose was too low. The CAMUS trial pushed the dose up to three times and followed men for nearly a year and a half. Not even the direction changed — the placebo group's scores fell by a hair more.
So the question was no longer is the effect big enough. It was is it doing anything at all.
A year later, the two groups' symptom scores almost overlapped, flow rates were the same, and prostate volume had crept up a little in both groups, again with no difference. The gap was so small that if you drew the two curves together you would think you had drawn one twice.
Then came the objection: maybe the dose was too low. The CAMUS trial pushed the dose up to three times and followed men for nearly a year and a half. Not even the direction changed — the placebo group's scores fell by a hair more.
So the question was no longer is the effect big enough. It was is it doing anything at all.
Numbers · What the STEP trial measured
The first: the STEP trial (Bent 2006, NEJM)Participants: 225 men with moderate-to-severe symptoms (AUA-SI ≥ 8; the AUA-SI is the American Urological Association's self-completed symptom questionnaire, where a higher score means worse symptoms), run by a team based at the University of California, San Francisco (UCSF) and other centersIntervention: standardized saw palmetto extract, 320 mg a day, against placebo, for 1 yearFunding: independent (the National Center for Complementary and Alternative Medicine, NCCAM, part of the US National Institutes of Health), with no manufacturer involvedBlinding: the placebo carried a melted-cheese flavor to match the smellPrimary endpoints: the AUA-SI symptom score and the maximum urinary flow rateResults:AUA-SI: down 0.68 points on saw palmetto and 0.72 points on placebo, a difference of 0.04 pointsMaximum flow rate: a difference of 0.43 mL/s between the groups, statistically indistinguishable from zeroProstate volume, urine left after voiding, quality of life, serum : no difference in any of themConclusion: 320 mg a day for a year did not improve moderate-to-severe BPH symptoms
Put those numbers back into the body. Both groups dropped by less than one point — and a drop that size is exactly what you get from doing nothing. The gap in maximum flow is smaller still, around half a milliliter per second; standing at the toilet you could not feel it. Prostate volume crept up in both groups, which means hyperplasia carried on through that whole year and nothing stopped it.
Numbers · CAMUS tripled the dose
The second: the CAMUS trial (Barry 2011, JAMA)Participants: 369 men with moderate-to-severe lower urinary tract symptoms at 11 clinical centers in North AmericaDose escalation: 320 mg a day to start, then 640 mg, then 960 mg, over 72 weeks in allPurpose: to test the dose was too low hypothesis — perhaps the earlier negative trials had simply used too littleResults:AUA-SI: down 2.20 points on saw palmetto and 2.99 points on placebo; a difference of 0.79 points in favor of placebo, not significant. By the trial's own statistics, even the estimate most favorable to saw palmetto was only 1.77 points better than placeboNone of the three dose steps was significantly better than placeboSecondary outcomes, including nocturia, peak flow, urine left after voiding, , sexual function and sleep quality: none beat placeboConclusion: even at three times the dose, saw palmetto was still no better than placebo
Why the dose-escalation design matters. Something with a real pharmacological action should show its hand when you raise the dose: a little more effect, or a little more side effect, the curve leaning one way or the other. That is called a dose-response relationship. CAMUS pushed the dose all the way to three times and the curve stayed flat — neither better nor worse.
A flat dose-response curve is an independent negative result in its own right, and far harder to explain away than no difference at a single dose. A single dose can still be blamed on the wrong dose; with three dose steps all flat, the simplest explanation left is that this substance is not acting in the human body.
Mechanism · No effect versus no action
Something that truly blocked 5α-reductase would leave fingerprints in the body that are hard to fake.After a prescription inhibitor of that class, several things follow in a row: DHT in the blood falls; over a few months the prostate genuinely shrinks a notch; and in the blood (a protein made by the prostate's lining cells) drops clearly too — fewer cells making it means less of it in the blood. All of these are direct consequences of the upstream step being blocked. They have nothing to do with the score you give yourself, and a placebo cannot forge them.
The two large trials measured two of these: STEP measured prostate volume and PSA, and CAMUS measured PSA again. The saw palmetto and placebo groups did not differ on either.
That sentence weighs far more than symptoms did not improve. It is not saying it blocked the enzyme, just not enough. It is saying it basically did not block it: the first link of the chain was not seen in people. If the first link does not happen, symptoms failing to improve is no surprise; it was settled upstream.
That also knocks down the last line of defense, works in vitro. The inhibition in the dish is real, but after a capsule has been through gut absorption and liver metabolism, the most likely explanation is that the amount reaching prostate tissue never gets near a concentration that would stop the enzyme.
Why this is more than a failure to reach statistical significance. That phrase only means a trial could not see clearly, and a larger one might still find something. Here, three independent lines — symptom score, flow rate, and the volume and PSA that should have moved first — all point to nearly zero, and trials large enough to do so have already boxed any possible effect into a very small range (CAMUS put the upper limit at just 1.77 points).
Evidence · The 2012 Cochrane update
The third: the 2012 update of the Cochrane systematic review (Tacklind and colleagues)Between 2002 and 2012 the number of randomized trials grew from 21 to 32, covering 5,666 men, and the newcomers included STEP and CAMUSAgainst placebo: symptom scores on the AUA-SI or the IPSS (the International Prostate Symptom Score, built on the same symptom questions as the AUA-SI), maximum urinary flow and nocturia showed no differenceThe early positive signals were diluted to nearly zero by large, strictly blinded trialsThe authors' conclusion: even at double and triple doses, saw palmetto did not improve urinary flow or shrink the prostate
The reversal between the 2002 and 2012 Cochrane conclusions is a classic case in evidence-based medicine. It matters because this is more than failing to reach statistical significance: several independent large trials, strict blinding and high doses ruled out the maybe it still helps a bit explanations one by one. The mechanism sounds reasonable; clinical reality is another matter.
How guidelines followed: the American Urological Association (AUA) BPH guideline, amended in 2023, states that the evidence does not support a benefit from saw palmetto for lower urinary tract symptoms and does not recommend it. Some European national guidelines still partly keep it, for historical reasons and because it is considered harmless for men with mild symptoms; positions differ from one body to another.
What separated the two waves of trials: the early ones were small, poorly blinded, manufacturer-funded, subject to publication bias, and did not control the placebo effect; the later ones had independent funding, strict blinding, large samples, enough follow-up time and many centers. Put simply: the more rigorously the trial was designed, the less effect it found.
Background · Why the market has not collapsed
The large trials came out, and the market did not collapse:Marketing inertia: saw palmetto is still one of the best-selling herbal supplements for BPHBeliefs lag behind: the impression that "someone said it works" is hard to shiftThe placebo effect plus natural swings in symptoms leave some users feeling better, while objective measures do not improveRegulation: in the United States, the 1994 DSHEA law lets supplements go on sale without first proving they work
Chapter 4
Other treatments and side effects
Without saw palmetto, BPH still has a whole ladder from mild to severe, and every rung aims at one specific link in the chain described earlier.
Rung 0: first check whether you need treatment at all. If symptoms are mild (AUA-SI < 8), with no urinary retention, no recurring urinary tract infections (UTIs) and no effect on the kidneys, the international guideline consensus is watchful waiting: a commonly quoted figure is that about 50% of men stay stable or even improve on their own, with a recheck every 6-12 months. Do not let "everyone your age should take a prostate supplement" push you along.
Rung 1: lifestyle. It moves how much fluid reaches the bladder, how tight that ring of smooth muscle is, and how irritated the bladder gets — all three are on the chain. Drinking less in the evening, cutting back on alcohol and coffee, and avoiding cold remedies that tighten smooth muscle each target one of those links.
Only above that come drugs: α-blockers that relax the smooth muscle (working within weeks), 5α-reductase inhibitors that shrink the gland (taking months), both together for moderate-to-severe symptoms, and surgery last.
Rung 0: first check whether you need treatment at all. If symptoms are mild (AUA-SI < 8), with no urinary retention, no recurring urinary tract infections (UTIs) and no effect on the kidneys, the international guideline consensus is watchful waiting: a commonly quoted figure is that about 50% of men stay stable or even improve on their own, with a recheck every 6-12 months. Do not let "everyone your age should take a prostate supplement" push you along.
Rung 1: lifestyle. It moves how much fluid reaches the bladder, how tight that ring of smooth muscle is, and how irritated the bladder gets — all three are on the chain. Drinking less in the evening, cutting back on alcohol and coffee, and avoiding cold remedies that tighten smooth muscle each target one of those links.
Only above that come drugs: α-blockers that relax the smooth muscle (working within weeks), 5α-reductase inhibitors that shrink the gland (taking months), both together for moderate-to-severe symptoms, and surgery last.
In practice · Which link each lifestyle step moves
Rung 1: lifestyle. The evidence behind these steps varies in strength, but each one can be traced to a specific link in the chain:Drink less after 19:00 to cut nocturia. A good share of nighttime waking is not a prostate problem at all; it is the glass of water before bed filling the bladder a few hours later. The outlet is already narrow, so once the bladder is full, the pressure more easily crosses the threshold that wakes you. Moving the fluid to daytime moves that filling to hours when you are awake.Cut back on alcohol, caffeine and soft drinks to ease urgency. Alcohol and caffeine work both ends at once: they increase urine output, so the bladder fills faster, and they irritate the bladder wall directly, so it signals "full" sooner. So one drink fewer mainly improves urgency, not flow rate. Knowing that keeps you from giving up just because the stream did not get stronger.Avoid over-the-counter anticholinergics (including some antihistamines) and decongestants containing pseudoephedrine, which can make voiding harder. The first weakens the bladder's contraction (it cannot push); the second tightens the ring of smooth muscle at the prostate and bladder neck (the cinch gets tighter). A bladder that cannot push against an outlet that is squeezed tighter is exactly why some men take one cold tablet and find passing urine clearly harder that night.Timed voiding: go on purpose every 2-3 hours rather than waiting for urgency. Bladder training: when urgency comes, count 30 seconds before you go. Both target the half of the symptoms the bladder was forced into: once the bladder wall has thickened and become sensitive it raises the alarm early, urging you to go when only a little is in, and holding on for those thirty seconds pushes the alarm line back a little at a time.Pelvic-floor training (Kegel exercises for men): can reduce dribbling after voiding.Manage constipation: a packed rectum sits right behind the bladder and prostate; it takes up room directly, and through a nerve reflex between rectum and bladder it also makes voiding less clean.Exercise and weight loss: men who carry fat around the waist (central obesity) tend to have worse BPH symptoms. This is an observed association, and unlike the items above it cannot be pinned to one physical link, so do not expect it to solve the problem on its own.
This rung has a genuinely limited ceiling, but it has something saw palmetto cannot offer: each of the items above can be traced to a concrete physical link, so you can judge for yourself which ones help you and which ones are irrelevant to you.
Clinical · The drug and surgery rungs
Rungs 2-4 are drugs and surgery, each aimed at a different link in the chain.Rung 2: α-blockers (tamsulosin, silodosin, doxazosin)
Mechanism: relax the smooth muscle of the prostate and bladder neck that α₁ receptors controlOnset: 1-2 weeksSymptom improvement: compared with before treatment, the AUA-SI falls by 4-6 points (part of which is placebo response); in STEP, the saw palmetto group's own score fell by only about 0.7 points, no different from placeboSide effects: orthostatic hypotension (blood pressure dropping when you stand up), dizziness, retrograde ejaculation (especially common with silodosin)Intraoperative floppy iris syndrome (IFIS): men taking tamsulosin face a higher risk during cataract surgery, so tell the eye surgeon beforehand
Those two side effects are spillover from the same mechanism. Retrograde ejaculation: during ejaculation, the ring of smooth muscle at the bladder neck should tighten and seal the exit so semen can only go forward; the drug relaxes it, so semen takes the path of less resistance, back into the bladder. IFIS: the iris muscle that widens the pupil also carries α₁ receptors; blocked for a long time, it loses tone, and during cataract surgery the iris billows like a sail. The drug is not doing anything wrong; the same receptor simply grows in more than one place.
Rung 3: 5α-reductase inhibitors (finasteride, dutasteride)
Mechanism: block testosterone from becoming DHT; the prostate shrinks by about 20-25%Slow onset: effects begin at 3-6 months and stabilize by 12 monthsSymptom improvement: the AUA-SI falls by 3-4 points drops by about 50%: PSA results have to be read with that in mindSide effects: lower libido in about 5%, erectile dysfunction in about 5%, breast enlargement in menPost-finasteride syndrome: there are reports of sexual side effects that persist after stopping; how common it is and what causes it remain disputed, and online accounts often go further than the evidenceSpecial value: for large prostates, it reduces acute urinary retention and the need for surgery (the MTOPS trial)
A falling PSA is not a lab error. The lining cells that secrete PSA really have become fewer, which is evidence the drug is working. But it sets a trap: a PSA that is quietly rising can be offset by exactly this drop and still look normal. So whenever you have a PSA test, tell the doctor you take this drug.
Rung 4: combination and surgery
An α-blocker plus a 5α-reductase inhibitor: for moderate-to-severe symptoms together with a large prostateA newer option: low-dose daily tadalafil, which acts on both erectile dysfunction and BPHMinimally invasive procedures: UroLift, Rezum water-vapor ablation, iTind, prostate artery embolization (PAE)Traditional surgery: transurethral resection of the prostate (TURP) and laser surgery (HoLEP, GreenLight), for severe symptoms or when drugs fail
Why combining the two drugs adds rather than repeats: one releases tone (working within weeks, without changing volume), the other takes away volume (taking months to move, but able to change the course of the disease). Each hits a different link in the chain, which is why stacking them gives an extra gain.
Evidence · Side by side with mainstream drugs
Saw palmetto side by side with mainstream drugs:| Dimension | Saw palmetto | Tamsulosin | Finasteride |
|---|---|---|---|
| Symptom improvement (AUA-SI) | ~0 | 4-6 points | 3-4 points |
| Onset | none | 1-2 weeks | 3-6 months |
| Price (US generics) | $15-40 a month | $5-10 a month | $5-15 a month |
| Insurance coverage | no | yes | yes |
| Side effects | placebo-level | orthostatic hypotension, ejaculation problems | sexual function, breast |
| Guideline recommendation | no | yes | yes |
One thing to watch when reading the table: the saw palmetto column is the difference against placebo, while the two drug columns are the improvement against before treatment, which includes placebo response too, so the two cannot simply be subtracted.
Read the table as one sentence: you spend more and buy an effect nobody can measure plus almost no side effects; the cheaper prescription gives you a clear symptom improvement plus a set of side effects you can manage with your doctor.
Saw palmetto's only clinical advantage is having few side effects. But that is precisely because human trials cannot detect any pharmacological action, so it does not cause the side effects of an α-blocker or a 5α-reductase inhibitor. Here no side effects is just the other face of no effect, not a strength. I felt better on it is mostly placebo, the passage of time and natural swings in symptoms.
Safety (its strongest side):
Acute side effects are uncommon: stomach upset, headache (about 2-5%)No clear liver toxicity, kidney toxicity or heavy-metal problems (unlike red yeast rice or tongkat ali)No known major drug interactions (the precautions around surgery and hormone therapy are in Should I use it?)So "it does no harm" roughly holds, but "it does no good" is the more accurate description
If you are uneasy about taking drugs:
Rung 0, watchful waiting, plus rung 1, lifestyle, already cover most mild casesIf you insist on a natural route: lycopene (a weak prostate-protection signal; getting it from food is fine); β-sitosterol (in vitro data, weak randomized trials); rye-grass pollen extract (Cernilton; the evidence is also weak)But natural treatment for BPH is low-yield overall, far below tamsulosin
Chapter 5
Should I use it?
First be clear about what you are buying. All saw palmetto reliably supplies is the feeling that I am doing something for myself. Human trials cannot detect any pharmacological action, so it will not hurt you, and it will not loosen that ring around the urethra either.
Once symptoms affect your life (AUA-SI ≥ 8), time itself has a cost. While the outlet stays cinched, the bladder stays overloaded; if one day it can no longer push, that is acute urinary retention — you cannot pass urine at all and need a catheter, so go to the emergency department at once. This is also where the prostate-shrinking drugs earn their keep: they cut not only the symptom score but the number of men who end up with retention or surgery.
But what if I really did feel better? The feeling is probably real; the cause is probably not saw palmetto. Symptoms already go up and down, you may have drunk less or slept earlier over the same days, and simply treating yourself lifts a subjective score by a notch. To tell them apart, look at what a placebo cannot move: a flow-rate test, the urine left after voiding, prostate volume.
If you really have BPH symptoms: see a urologist, and do not spend 6-12 months on saw palmetto — that time can let symptoms worsen or cost you a better treatment.
Once symptoms affect your life (AUA-SI ≥ 8), time itself has a cost. While the outlet stays cinched, the bladder stays overloaded; if one day it can no longer push, that is acute urinary retention — you cannot pass urine at all and need a catheter, so go to the emergency department at once. This is also where the prostate-shrinking drugs earn their keep: they cut not only the symptom score but the number of men who end up with retention or surgery.
But what if I really did feel better? The feeling is probably real; the cause is probably not saw palmetto. Symptoms already go up and down, you may have drunk less or slept earlier over the same days, and simply treating yourself lifts a subjective score by a notch. To tell them apart, look at what a placebo cannot move: a flow-rate test, the urine left after voiding, prostate volume.
If you really have BPH symptoms: see a urologist, and do not spend 6-12 months on saw palmetto — that time can let symptoms worsen or cost you a better treatment.
Clinical · Five cases where it is the wrong choice
Situations where you should not use it (the great majority):① Moderate-to-severe BPH: saw palmetto failed in large randomized trials. The right tools are an α-blocker, a 5α-reductase inhibitor or both, and using saw palmetto only delays effective treatment.
② Acute urinary retention, recurring urinary tract infections, kidneys affected
Urgent — go straight to urologySaw palmetto is entirely the wrong toolIf you cannot pass urine at all, go to the emergency department now
③ Preventive thinking — "I'm getting older, I should start a prostate supplement": no randomized trial shows saw palmetto prevents BPH from progressing. It is wasted money.
④ You already take an α-blocker and think adding saw palmetto will work in synergy: there is no evidence that adding it does better. You are only stacking costs.
⑤ Suspected prostate cancer or a rising : saw palmetto neither prevents nor treats prostate cancer. See a urologist for an evaluation (a digital rectal exam, DRE; PSA; and a biopsy or MRI if needed).
Item ④ deserves one more sentence. For synergy to exist, two different points of action each have to work first; only then can they add up. In the human body saw palmetto has no evidence even for its first point of action (the volume and PSA measured in STEP, and the PSA measured in CAMUS, did not move). Stacking it on does not buy double insurance; it just spends two amounts of money to buy one.
Item ⑤ is the highest-risk line in this whole story. Saw palmetto does not lower PSA, so at least it will not hide the signal; but it does use up time, and in front of a rising PSA, time is the one thing you cannot return.
In practice · The one barely defensible use
Situations where it is barely acceptable (a narrow band):① Mild symptoms (AUA-SI 4-7), a strong refusal of prescription drugs, and lifestyle changes already in place
Here saw palmetto works as a placebo booster; you may feel better subjectivelyIt is a safe way of doing something, psychologically — precisely because trials in people cannot detect any pharmacological actionTo be honest: you may be paying a monthly fee for a placebo effectDo not go past 6 months, and recheck your AUA-SI when the time is up: if it has not improved, switch to an α-blocker
② Traditional uses beyond BPH (no strong evidence)
Folk use for urinary complaints and male vigor, with very weak evidenceNot recommended
The key words here are lifestyle changes already in place. That earlier rung does not mean try something casually first: drinking less in the evening, less alcohol and coffee, going through the cold and allergy medicines you take, timed voiding — each of these aims at a specific link in the chain, and together they deliver more improvement than saw palmetto delivered in any large trial. Finish them before you consider buying a bottle; the order cannot be reversed.
Do not skip the recheck either. Give yourself a clear deadline and a clear measure (your AUA-SI score), and if there is no improvement by then, change course. The most expensive cost of a supplement was never the money. It is the feeling that I am already dealing with this, which lets you stay comfortably away from a doctor.
In practice · If you still decide to use it
How to choose on quality (if you decide to use it):A standardized oil extract (fatty-acid content ≥ 85%)An extract with a history in randomized trials, such as Permixon® or SabalSelect®Third-party certification (USP, NSF, ConsumerLab)Usual dose: 320 mg a day (the dose the randomized trials used)Skip the prostate combination formulas: the full stack of rye-grass pollen extract, zinc, lycopene and nettle with saw palmetto makes it impossible to tell which ingredient is doing what, and gives poor value
Why combination formulas are especially poor value. With five or six things in one bottle, if anything goes wrong you do not know which to stop, and if something actually works you do not know which to credit. More practically, to fit that many ingredients into one capsule, each one is usually below the dose its own trials used — you are buying a list that looks complete, not an effective dose of any single ingredient.
Safety and interactions (its low-risk side):
A few people get stomach upset or headacheA rare bleeding risk (there is an in-vitro antiplatelet signal): stop 1-2 weeks before surgeryA theoretical effect on hormone therapy: take care combining it with finasteride or testosterone replacement therapy ()
Myth · What feeling better actually is
It really made me feel better usually rests on a few things:The placebo effect on subjective BPH scores is very strong: the placebo group's own AUA-SI can improve by anywhere from under 1 point to about 3 (0.72 points in STEP, 2.99 in CAMUS)Symptoms swing on their own: warmer weather, less alcohol and coffee, and weight loss can all bring improvement, and the credit goes to saw palmettoThe satisfaction of having done something: a psychological benefit, not clinical effectivenessObjective measurement: a flow-rate test, the urine left after voiding and prostate volume are what separate these
Notice how big that first number is. The improvement the placebo group produces on its own is already several times the gap between the saw palmetto and placebo groups. In other words, a man who took saw palmetto and felt clearly better is feeling a real improvement; it is just that the same improvement showed up in the men taking sugar pills.
Why BPH in particular is so easy to be fooled by is worth thinking through:
The symptoms are a score you give yourself, not a number an instrument reads, so expectation walks straight into the reading;Symptoms already go up and down, and people tend to start taking something on their worst few days — after which they naturally improve. This is regression to the mean (after an extreme reading, the next one tends to sit closer to usual);Over the same stretch you often changed something else too: drank less, went to bed earlier, the weather warmed up, and the bottle gets all the credit.
The only way out of this loop is a reading you cannot influence: the flow-rate curve, the residual urine on ultrasound, prostate volume. Those three do not care about your mood.
In practice · Three questions for the next supplement
> Saw palmetto is a relatively safe supplement that failed in rigorous trials — it will not harm you, and it also will not treat your BPH> Large independent randomized trials (STEP, CAMUS) and the 2012 Cochrane review have made that clear
> The American Urological Association (AUA) 2023 guideline explicitly does not recommend it
> It is the classic counterexample of positive early, negative in large trials, and it teaches three things:
> 1. A positive result from small studies, manufacturer funding and weak blinding is not a true effect
> 2. A mechanism that sounds reasonable is not the same as clinically effective
> 3. The standard of judgment is a large, independent randomized trial, not influencers, marketing or forum posts
Turn those three around and they stop being only about saw palmetto. Next time a supplement comes with an unusually smooth mechanism story, ask three questions: is there a large, independently funded randomized trial? Could the participants really not tell what they were taking? Did an objective measure that a placebo cannot forge move along with it? Only once all three have answers do you get to ask how big the effect is.
References · 6
- Sandhu, J. S., Bixler, B. R., Dahm, P., Goueli, R., Kirkby, E., Stoffel, J. T., & Wilt, T. J. (2024). Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. Journal of Urology, 211(1), 11-19. AUA notes that the evidence does not support a benefit from saw palmetto and does not recommend it for LUTS/BPH. 10.1097/JU.0000000000003698
- Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984). The development of human benign prostatic hyperplasia with age. Journal of Urology, 132(3), 474-479. Pooled data from 10 independent autopsy studies, more than 1,000 prostates. Pathological BPH prevalence is 8% in the fourth decade (ages 31-40) and 50% at ages 51-60; the abstract gives no figure for men in their 70s or 80s. Normal prostate ~20 ± 6 g at ages 21-30; only 4% of prostates in men over 70 exceed 100 g; BPH growth probably begins before age 30 (abstract, PMID 6206240). 10.1016/S0022-5347(17)49698-4
- Tacklind, J., MacDonald, R., Rutks, I., Stanke, J. U., & Wilt, T. J. (2012). Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews, (12), CD001423. Updated meta of 32 trials, N=5,666: no difference vs placebo on urinary symptom scores or flow rate. 10.1002/14651858.CD001423.pub3
- Wilt, T., Ishani, A., & Mac Donald, R. (2002). Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews, (3), CD001423. 21 trials, 3,139 men, 4-48 weeks. Versus placebo: urinary symptom score WMD -1.41 points (1 study), self-rated improvement RR 1.76 (6 studies), nocturia -0.76 times per evening, peak flow +1.86 mL/s; similar to finasteride. The reviewers' conclusion - 'mild to moderate improvement in urinary symptoms and flow measures' - qualifies the size of the improvement, not the men's disease severity. Long-term effectiveness and prevention of complications were unknown (abstract, PMID 12137626). 10.1002/14651858.cd001423
- Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., & Avins, A. L. (2006). Saw palmetto for benign prostatic hyperplasia. New England Journal of Medicine, 354(6), 557-566. STEP trial: 320 mg/day saw palmetto × 1 yr vs placebo in 225 men with moderate-severe BPH — no difference in AUA-SI, max urinary flow, prostate size, or QoL. Saw palmetto extract 160 mg twice daily. Between-group differences: AUASI 0.04 point (-0.93 to 1.01) and maximal urinary flow 0.43 mL/min (-0.52 to 1.38); no difference in prostate size, post-void residual volume, quality of life or PSA (abstract, PMID 16467543). 10.1056/NEJMoa053085
- Barry, M. J., Meleth, S., Lee, J. Y., Kreder, K. J., Avins, A. L., Nickel, J. C., et al. (2011). Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial (CAMUS). JAMA, 306(12), 1344-1351. Dose-escalation 320 → 640 → 960 mg/day × 72 wk in 369 men — no benefit at any dose vs placebo. The group mean difference in AUASI change at 72 weeks was 0.79 points favouring placebo (upper bound of the one-sided 95% CI most favourable to saw palmetto 1.77; one-sided P = .91). Saw palmetto was no better for any secondary outcome - urinary bother, nocturia, peak uroflow, postvoid residual volume, PSA, global assessments, sexual function, continence, sleep and prostatitis symptoms; prostate volume is not among the listed outcomes (abstract, PMID 21954478; full text, PMC3326341). 10.1001/jama.2011.1364